A class of compounds with a common thiazolo[3,2‐a]pyrimidinone motif has been developed as generalinhibitors of Bcl‐2 familyproteins. The lead compound was originally identified in a random screening of a small compound library using a fluorescence polarization‐based competitive binding assay. Its binding to the Bcl‐xL protein was further confirmed by 15N‐HSQC NMR experiments. Structural modifications
一类具有常见的噻唑并[3,2- a ]嘧啶酮基序的化合物已被开发为Bcl-2家族蛋白的一般抑制剂。最初使用基于荧光偏振的竞争结合测定法对小型化合物库进行随机筛选来鉴定先导化合物。15 N-HSQC NMR实验进一步证实了其与Bcl-x L蛋白的结合。分子模型研究的结果指导了对先导化合物的结构修饰。与先导化合物相比,在获得的42种化合物中,许多化合物与Bcl-2家族蛋白的结合亲和力大大提高。最有效的化合物BCL‐LZH‐ 40抑制BH3肽与Bcl‐x L的结合和Bcl-2和Mcl-1的与抑制常数(ķ我)的17,534和200N的中号,分别。